ArticleJournal of the National Cancer Institute2014
Development and validation of insulin-like growth factor-1 score to assess hepatic reserve in hepatocellular carcinoma.
Abstract read
In one paragraph
Article in Journal of the National Cancer Institute, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Evaluating the role of preoperative serum insulin-like growth factor 1 as a predictor of survival and recurrence for patients with resectable hepatocellular carcinoma.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2026Article
- Circulating Galectin-3: A Prognostic Biomarker in Hepatocellular Carcinoma.Journal of immunotherapy and precision oncology · 2024Article
- Development of a Novel Comprehensive Hepatocellular Carcinoma Outcome Prognostic Scoring System With Integration of Imaging Features.The oncologist · 2024Article
- Serum HIF-1α, IGF-1 and IGFBP-3 correlate to recurrence and overall survival in early-stage hepatocellular carcinoma patients.Biomarkers in medicine · 2024Article
- Serum IGF-1 Scores and Clinical Outcomes in the Phase III IMbrave150 Study of Atezolizumab Plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2022Article
- Article
- Blockade of growth hormone receptor signaling by using pegvisomant: A functional therapeutic strategy in hepatocellular carcinoma.Frontiers in oncology · 2022Article
- HepatoScore-14: Measures of Biological Heterogeneity Significantly Improve Prediction of Hepatocellular Carcinoma Risk.Hepatology (Baltimore, Md.) · 2021Article
- Article
- Integrated Bioinformatics Analysis Reveals Key Candidate Genes and Pathways Associated With Clinical Outcome in Hepatocellular Carcinoma.Frontiers in genetics · 2020Article
- Prognostic Significance of Serum Insulin-Like Growth Factor-1 in Hepatocellular Cancer Patients: A Validation Study.Journal of hepatocellular carcinoma · 2020Article
- Article
- Validation of insulin-like growth factor-1 as a prognostic parameter in patients with hepatocellular carcinoma in a European cohort.BMC cancer · 2018Article
- Article
- Article
- Systematic tracking of disrupted modules identifies significant genes and pathways in hepatocellular carcinoma.Oncology letters · 2016Article
- Validation of a Preclinical Model of Diethylnitrosamine-Induced Hepatic Neoplasia in Yucatan Miniature Pigs.Oncology · 2016Article
- Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there?World journal of gastroenterology · 2015Review
- Validation of an IGF-CTP scoring system for assessing hepatic reserve in Egyptian patients with hepatocellular carcinoma.Oncotarget · 2015Article
- Obesity Early in Adulthood Increases Risk but Does Not Affect Outcomes of Hepatocellular Carcinoma.Gastroenterology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Ahmed O KasebAffiliations of authors: Department of Gastrointestinal Medical Oncology (AOK, MMH, YKC, SC, HM H, KR, JLA, RW), Department of Biostatistics (LX, JSM), Department of Systems Biology (JSL), Department of Surgical Oncology (JNV, TA, CC, SAC), Department of Radiation Oncology (SK), Department of Interventional Radiology (MW), and Department of Pathology (AR), University of Texas MD Anderson Cancer Center, Houston, TX; Department of Hepatology, Baylor College of Medicine, Houston, TX (JMV, PJ). akaseb@mdanderson.org.
Lianchun XiaoAffiliations of authors: Department of Gastrointestinal Medical Oncology (AOK, MMH, YKC, SC, HM H, KR, JLA, RW), Department of Biostatistics (LX, JSM), Department of Systems Biology (JSL), Department of Surgical Oncology (JNV, TA, CC, SAC), Department of Radiation Oncology (SK), Department of Interventional Radiology (MW), and Department of Pathology (AR), University of Texas MD Anderson Cancer Center, Houston, TX; Department of Hepatology, Baylor College of Medicine, Houston, TX (JMV, PJ).
Manal M HassanAffiliations of authors: Department of Gastrointestinal Medical Oncology (AOK, MMH, YKC, SC, HM H, KR, JLA, RW), Department of Biostatistics (LX, JSM), Department of Systems Biology (JSL), Department of Surgical Oncology (JNV, TA, CC, SAC), Department of Radiation Oncology (SK), Department of Interventional Radiology (MW), and Department of Pathology (AR), University of Texas MD Anderson Cancer Center, Houston, TX; Department of Hepatology, Baylor College of Medicine, Houston, TX (JMV, PJ).
Young Kwang ChaeAffiliations of authors: Department of Gastrointestinal Medical Oncology (AOK, MMH, YKC, SC, HM H, KR, JLA, RW), Department of Biostatistics (LX, JSM), Department of Systems Biology (JSL), Department of Surgical Oncology (JNV, TA, CC, SAC), Department of Radiation Oncology (SK), Department of Interventional Radiology (MW), and Department of Pathology (AR), University of Texas MD Anderson Cancer Center, Houston, TX; Department of Hepatology, Baylor College of Medicine, Houston, TX (JMV, PJ).
Ju-Seog LeeAffiliations of authors: Department of Gastrointestinal Medical Oncology (AOK, MMH, YKC, SC, HM H, KR, JLA, RW), Department of Biostatistics (LX, JSM), Department of Systems Biology (JSL), Department of Surgical Oncology (JNV, TA, CC, SAC), Department of Radiation Oncology (SK), Department of Interventional Radiology (MW), and Department of Pathology (AR), University of Texas MD Anderson Cancer Center, Houston, TX; Department of Hepatology, Baylor College of Medicine, Houston, TX (JMV, PJ).
Jean-Nicolas VautheyAffiliations of authors: Department of Gastrointestinal Medical Oncology (AOK, MMH, YKC, SC, HM H, KR, JLA, RW), Department of Biostatistics (LX, JSM), Department of Systems Biology (JSL), Department of Surgical Oncology (JNV, TA, CC, SAC), Department of Radiation Oncology (SK), Department of Interventional Radiology (MW), and Department of Pathology (AR), University of Texas MD Anderson Cancer Center, Houston, TX; Department of Hepatology, Baylor College of Medicine, Houston, TX (JMV, PJ).
Sunil KrishnanAffiliations of authors: Department of Gastrointestinal Medical Oncology (AOK, MMH, YKC, SC, HM H, KR, JLA, RW), Department of Biostatistics (LX, JSM), Department of Systems Biology (JSL), Department of Surgical Oncology (JNV, TA, CC, SAC), Department of Radiation Oncology (SK), Department of Interventional Radiology (MW), and Department of Pathology (AR), University of Texas MD Anderson Cancer Center, Houston, TX; Department of Hepatology, Baylor College of Medicine, Houston, TX (JMV, PJ).
Sheree CheungAffiliations of authors: Department of Gastrointestinal Medical Oncology (AOK, MMH, YKC, SC, HM H, KR, JLA, RW), Department of Biostatistics (LX, JSM), Department of Systems Biology (JSL), Department of Surgical Oncology (JNV, TA, CC, SAC), Department of Radiation Oncology (SK), Department of Interventional Radiology (MW), and Department of Pathology (AR), University of Texas MD Anderson Cancer Center, Houston, TX; Department of Hepatology, Baylor College of Medicine, Houston, TX (JMV, PJ).
Hesham M HassaboAffiliations of authors: Department of Gastrointestinal Medical Oncology (AOK, MMH, YKC, SC, HM H, KR, JLA, RW), Department of Biostatistics (LX, JSM), Department of Systems Biology (JSL), Department of Surgical Oncology (JNV, TA, CC, SAC), Department of Radiation Oncology (SK), Department of Interventional Radiology (MW), and Department of Pathology (AR), University of Texas MD Anderson Cancer Center, Houston, TX; Department of Hepatology, Baylor College of Medicine, Houston, TX (JMV, PJ).
Thomas AloiaAffiliations of authors: Department of Gastrointestinal Medical Oncology (AOK, MMH, YKC, SC, HM H, KR, JLA, RW), Department of Biostatistics (LX, JSM), Department of Systems Biology (JSL), Department of Surgical Oncology (JNV, TA, CC, SAC), Department of Radiation Oncology (SK), Department of Interventional Radiology (MW), and Department of Pathology (AR), University of Texas MD Anderson Cancer Center, Houston, TX; Department of Hepatology, Baylor College of Medicine, Houston, TX (JMV, PJ).
Claudius ConradAffiliations of authors: Department of Gastrointestinal Medical Oncology (AOK, MMH, YKC, SC, HM H, KR, JLA, RW), Department of Biostatistics (LX, JSM), Department of Systems Biology (JSL), Department of Surgical Oncology (JNV, TA, CC, SAC), Department of Radiation Oncology (SK), Department of Interventional Radiology (MW), and Department of Pathology (AR), University of Texas MD Anderson Cancer Center, Houston, TX; Department of Hepatology, Baylor College of Medicine, Houston, TX (JMV, PJ).
Steven A CurleyAffiliations of authors: Department of Gastrointestinal Medical Oncology (AOK, MMH, YKC, SC, HM H, KR, JLA, RW), Department of Biostatistics (LX, JSM), Department of Systems Biology (JSL), Department of Surgical Oncology (JNV, TA, CC, SAC), Department of Radiation Oncology (SK), Department of Interventional Radiology (MW), and Department of Pathology (AR), University of Texas MD Anderson Cancer Center, Houston, TX; Department of Hepatology, Baylor College of Medicine, Houston, TX (JMV, PJ).
John M VierlingAffiliations of authors: Department of Gastrointestinal Medical Oncology (AOK, MMH, YKC, SC, HM H, KR, JLA, RW), Department of Biostatistics (LX, JSM), Department of Systems Biology (JSL), Department of Surgical Oncology (JNV, TA, CC, SAC), Department of Radiation Oncology (SK), Department of Interventional Radiology (MW), and Department of Pathology (AR), University of Texas MD Anderson Cancer Center, Houston, TX; Department of Hepatology, Baylor College of Medicine, Houston, TX (JMV, PJ).
Prasun JalalAffiliations of authors: Department of Gastrointestinal Medical Oncology (AOK, MMH, YKC, SC, HM H, KR, JLA, RW), Department of Biostatistics (LX, JSM), Department of Systems Biology (JSL), Department of Surgical Oncology (JNV, TA, CC, SAC), Department of Radiation Oncology (SK), Department of Interventional Radiology (MW), and Department of Pathology (AR), University of Texas MD Anderson Cancer Center, Houston, TX; Department of Hepatology, Baylor College of Medicine, Houston, TX (JMV, PJ).
Kanwal RaghavAffiliations of authors: Department of Gastrointestinal Medical Oncology (AOK, MMH, YKC, SC, HM H, KR, JLA, RW), Department of Biostatistics (LX, JSM), Department of Systems Biology (JSL), Department of Surgical Oncology (JNV, TA, CC, SAC), Department of Radiation Oncology (SK), Department of Interventional Radiology (MW), and Department of Pathology (AR), University of Texas MD Anderson Cancer Center, Houston, TX; Department of Hepatology, Baylor College of Medicine, Houston, TX (JMV, PJ).
Michael WallaceAffiliations of authors: Department of Gastrointestinal Medical Oncology (AOK, MMH, YKC, SC, HM H, KR, JLA, RW), Department of Biostatistics (LX, JSM), Department of Systems Biology (JSL), Department of Surgical Oncology (JNV, TA, CC, SAC), Department of Radiation Oncology (SK), Department of Interventional Radiology (MW), and Department of Pathology (AR), University of Texas MD Anderson Cancer Center, Houston, TX; Department of Hepatology, Baylor College of Medicine, Houston, TX (JMV, PJ).
Asif RashidAffiliations of authors: Department of Gastrointestinal Medical Oncology (AOK, MMH, YKC, SC, HM H, KR, JLA, RW), Department of Biostatistics (LX, JSM), Department of Systems Biology (JSL), Department of Surgical Oncology (JNV, TA, CC, SAC), Department of Radiation Oncology (SK), Department of Interventional Radiology (MW), and Department of Pathology (AR), University of Texas MD Anderson Cancer Center, Houston, TX; Department of Hepatology, Baylor College of Medicine, Houston, TX (JMV, PJ).
James L AbbruzzeseAffiliations of authors: Department of Gastrointestinal Medical Oncology (AOK, MMH, YKC, SC, HM H, KR, JLA, RW), Department of Biostatistics (LX, JSM), Department of Systems Biology (JSL), Department of Surgical Oncology (JNV, TA, CC, SAC), Department of Radiation Oncology (SK), Department of Interventional Radiology (MW), and Department of Pathology (AR), University of Texas MD Anderson Cancer Center, Houston, TX; Department of Hepatology, Baylor College of Medicine, Houston, TX (JMV, PJ).
Robert A WolffAffiliations of authors: Department of Gastrointestinal Medical Oncology (AOK, MMH, YKC, SC, HM H, KR, JLA, RW), Department of Biostatistics (LX, JSM), Department of Systems Biology (JSL), Department of Surgical Oncology (JNV, TA, CC, SAC), Department of Radiation Oncology (SK), Department of Interventional Radiology (MW), and Department of Pathology (AR), University of Texas MD Anderson Cancer Center, Houston, TX; Department of Hepatology, Baylor College of Medicine, Houston, TX (JMV, PJ).
Jeffrey S MorrisAffiliations of authors: Department of Gastrointestinal Medical Oncology (AOK, MMH, YKC, SC, HM H, KR, JLA, RW), Department of Biostatistics (LX, JSM), Department of Systems Biology (JSL), Department of Surgical Oncology (JNV, TA, CC, SAC), Department of Radiation Oncology (SK), Department of Interventional Radiology (MW), and Department of Pathology (AR), University of Texas MD Anderson Cancer Center, Houston, TX; Department of Hepatology, Baylor College of Medicine, Houston, TX (JMV, PJ).
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MCenter for Clinical and Translational Sciences (CCTS)UL1TR000371 · NCATS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MCPHERSON, DAVID D · 2012 to 2016
$13.4MMolecular Epidemiology of Chronic Liver DiseasesK07CA106458 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HASSAN, MANAL METWALLY · 2005 to 2009
$681kIntegrating plasma IGF-1 into novel classification of hepatocellular carcinomaR21CA170035 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KASEB, AHMED · 2012 to 2013
$366kNCATS NIH HHS UL1 TR000371NCI NIH HHS CA016672NCI NIH HHS CA106458-01NCI NIH HHS CA170035-01NCI NIH HHS P30 CA016672
Abstract
backgroundChild-Turcotte-Pugh (CTP) score is the standard tool to assess hepatic reserve in hepatocellular carcinoma (HCC), and CTP-A is the classic group for active therapy. However, CTP stratification accuracy has been questioned. We hypothesized that plasma insulin-like growth factor 1 (IGF-1) is a valid surrogate for hepatic reserve to replace the subjective parameters in CTP score to improve its prognostic accuracy.
methodsWe retrospectively tested plasma IGF-1 levels in the training set (n = 310) from MD Anderson Cancer Center. Recursive partitioning identified three optimal IGF-1 ranges that correlated with overall survival (OS): greater than 50 ng/mL = 1 point; 26 to 50 ng/mL = 2 points; and less than 26 ng/mL = 3 points. We modified the CTP score by replacing ascites and encephalopathy grading with plasma IGF-1 value (IGF-CTP) and subjected both scores to log-rank analysis. Harrell's C-index and U-statistics were used to compare the prognostic performance of both scores in both the training and validation cohorts (n = 155). All statistical tests were two-sided.
resultsPatients' stratification was statistically significantly stronger for IGF-CTP than CTP score for the training (P = .003) and the validation cohort (P = .005). Patients reclassified by IGF-CTP relative to their original CTP score were better stratified by their new risk groups. Most important, patients classified as A by CTP but B by IGF-CTP had statistically significantly worse OS than those who remained under class A by IGF-CTP in both cohorts (P = .03 and P < .001, respectively, from Cox regression models). AB patients had a worse OS than AA patients in both the training and validation set (hazard ratio [HR] = 1.45, 95% confidence interval [CI] = 1.03 to 2.04, P = .03; HR = 2.83, 95% CI = 1.65 to 4.85, P < .001, respectively).
conclusionsThe IGF-CTP score is simple, blood-based, and cost-effective, stratified HCC better than CTP score, and validated well on two independent cohorts. International validation studies are warranted.
Indexed as
Carcinoma, HepatocellularCohort StudiesEnzyme-Linked Immunosorbent AssayHumansInsulin-Like Growth Factor IKaplan-Meier EstimateLiverLiver NeoplasmsPrognosisProportional Hazards ModelsReproducibility of ResultsRetrospective StudiesInsulin-Like Growth Factor I
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.